Experience Eternal Romance with Exquisite Blue Diamonds by ALUXE

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection -  Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection -  Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your presence is the greatest protection for my love. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection -  Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection -  Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection -  Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-15

Kincora and AngloGold Ashanti’s First Drilling Program

The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti).New district-scale potential with up to eight large intrusive complex targets to be drill-tested for the first time in this initial first phase program.Approximately 6 to 8 drill holes for an estimated 4000-5000 metres budgeted before the summer break. Kincora is managing the program and will receive a 10% management fee. The program is the first by Kincora in partnership with AngloGold Ashanti, which has the right to spend up to A$50 million to earn an 80% interest in the Nyngan and Nevertire Projects.Fleet Space Technologies Pty Ltd's (Fleet Space) ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys at the Nyngan Project are progressing well and are expected to complement upcoming drilling.Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (TSXV: KCC) (ASX: KCC), (Kincora or the Company) is pleased to outline plans for the next chapter of copper-gold focused drilling in the Macquarie Arc, Central West New South Wales (NSW) with a first program in partnership with and funded by AngloGold Ashanti to shortly commence at the Nyngan Project.Sam Spring, President and CEO of Kincora, commented: "We are very excited by the potential of the Northern Junee-Narromine belt where we are seeking not to just confirm a new significant porphyry Cu-Au deposit but a new district and series of discoveries. The strategic appeal and value of a new porphyry district has been clearly illustrated in the Vicuña district with corporate activities by BHP and Lundin Mining this month supporting over C$8 billion of value being recognised for a cluster of four new major discoveries. Recent planning and targeting activities with our partner AngloGold Ashanti has significantly expanded the number of targets, the drilling activities needed and planned to test a series of major and previously undrilled interpreted magmatic complex targets at the Nyngan Project. Initially we are aiming to test up to eight new major intrusive system complex targets before year end in this first phase program which focuses on the very compelling northern Nyngan "Ace of Spades" region.Recent neighbouring explorer drilling is also supporting the potential of a series of Macquarie Arc intrusive complexes to the immediate east of the "Ace of Spades" target area along a potentially important common transverse structure providing further encouragement to the potential of a new porphyry district scale opportunity."BackgroundThe undercover extensions of the renowned Macquarie Arc porphyry copper-gold geology are globally significant exploration opportunities offering new district(s) scale discovery potential. The region has attracted four earn-in and joint venture agreements in the last 12 months supporting potentially over $200 million in exploration and development expenditure.The most recent notable example of a new emerging globally significant porphyry district is the Vicuña district in the central Andes in Argentina on the border of Chile, which is largely consolidated by Lundin group entities and BHP and situated at over 4000m altitude 1.Within this district NGEX Resources Inc in 2009 held three early-stage exploration projects and, at the time, had a market capitalisation of approximately C$40 million. These same projects are all still at a pre-development phase but have yielded four large-scale discoveries currently valued at over C$8 billion 2.In comparison, the central west of NSW benefits from multiple world-class mines, existing infrastructure, high-quality publicly available exploration data and an existing mineral endowment of over 160 million gold equivalent ounces 3. Regional geophysics strongly indicates that Kincora's Nyngan license hosts the largest volcano-intrusive complex of the Macquarie Arc, which is almost untested, offering new district scale potential.Kincora, as the early entrant, has secured a district scale position in the interpreted shallow-to-moderate covered core sections of the Northern Junee-Narromine Belt (NJNB) by pegging Nyngan and Nevertire which are now in partnership with AngloGold Ashanti 4.The imminent first-ever drilling program at the northern portion of the Nyngan Project will focus on the "Ace of Spades" region and test a wide range of untested, large intrusive-related Cu-Au targets. The program seeks to confirm the potential for a series of new Macquarie Arc intrusive complexes and provide vectors for follow up drilling - see Figure 1.Subject to permitting, access and weather conditions, the drilling program is anticipated to commence from mid September and will continue until the summer break, comprising up to eight holes for an estimated 4000-5000 metres.Recent planning and targeting activities with our partner AngloGold Ashanti have significantly expanded the number of targets, the drilling necessary to test a series of major and previously-undrilled interpreted magmatic complex targets at the Nyngan Project. This first program will test the potential for up to eight separate large intrusive complex targets.The program will comprise cost-effective mud-rotary drilling through the post mineral cover sequence with diamond core drilling upon refusal and testing of the targeted basement.Kincora is managing the exploration program and will receive a 10% management fee as the program is funded by AngloGold Ashanti via the up to $50 million earn-in and joint venture agreement for the Nyngan and Nevertire Projects.These drill targets include an existing high priority large intrusive complex target, which is currently the focus of Fleet Space's ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys within the northern portion of the Nyngan Project 5.  Figure 1: District-scale series of major and untested magmatic complex targets with in the northern Nyngan "Ace of Spades" region that potentially represent the largest volcano-intrusive complex of the Macquarie Arc.  Kincora is managing the exploration program and will receive a 10% management feeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/219846_kincora.jpgThe geophysical surveys are seeking to map and refine the interpretation of the paleo-surface and basement rocks and refine modeling of the targeted alteration, intrusions and structures.Recent neighbouring exploration drilling by Inflection Resources ("Inflection") is further supporting the potential of a series of Macquarie Arc intrusives to the immediate east of the "Ace of Spades" target area at Nyngan. Inflection has announced encouraging results at the Canonba target situated on the license boundary to the Nyngan Project, and located approximately 5km from its Duck Creek target, which is a Phase 2 designated project with its earn-in and joint venture partner AngloGold Ashanti 6. The Canonba, Duck Creek and Ace of Spades target areas potentially host important common transverse structures providing further encouragement about the potential of a new district-scale porphyry opportunity.About the Nyngan ProjectThe Nyngan license (Exploration Licence 8929) was the first ground Kincora secured in NSW. It is a large 762km2 direct application tenement granted by the NSW State Government covering a significant portion of the interpreted under cover section of the northern Junee-Narromine Belt 7. The Junee-Narromine Belt is one of the two largest belts of the Macquarie Arc, Australia's foremost porphyry belt, which hosts a mineral endowment of over 160 million gold equivalent ounces.The license hosts limited, but encouraging, prior explorer drilling that has been inadequately followed up, with regional geophysics supporting a new potential district-scale setting hosting interpreted, large-scale, intrusive complex targets.In May 2024, Kincora signed a definitive multiple-phase Earn-in and Joint Venture Agreement (Agreement) over the Nyngan and Nevertire licences with a wholly owned subsidiary of AngloGold Ashanti plc (NYSE: AU) (JSE: ANG), the world's fourth largest gold miner by production, which has a successful track record for Greenfields discovery success.AngloGold Ashanti has the right to spend up to A$50 million to earn an 80% interest through:A$25 million of exploration expenditure to earn a 70% joint venture interest (Phase I) including a minimum A$2 million expenditure obligation, with Kincora the initial operator for a 10% management fee. Completion of a Pre-Feasibility Study (PFS) or funding of a further $25 million of expenditure to earn a 80% joint venture interest (Phase II).In July 2024, separate to the Agreement with AngloGold Ashanti, Kincora formed a partnership with Fleet Space Technologies Pty Ltd (Fleet Space) to undertake Ambient Noise Tomography (ANT) and gravity geophysical surveys under a research and development grant at the Nyngan Project.Within the immediate district Fleet Space recently completed the world's largest ANT survey, undertaking a number of project-specific surveys that defined multiple new targets and built a proprietary AI-powered district-scale copper prospectivity map 8,9,10.The Fleet Space surveys are anticipated to complement Kincora and AngloGold Ashanti's planned exploration and upcoming drilling.About KincoraKincora Copper is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.comReferences:1 Lundin Mining and BHP to Acquire Filo and Form a 50/50 Joint Venture to Progress the Filo del Sol and Josemaria Projects - BHP and Lundin Mining press releases July 29, 20242 NGEX Minerals Corporate Presentation (July 2024) and market values as at July 29, 2024 (from peer transactions and TSXV market capitalization)3 Sourced from MinEx Consulting for Kincora4 AngloGold Ashanti to earn-in to the NJNB Project - Kincora press release May 28, 20245 ANT and Gravity Geophysical Surveys at the Nyngan Project - Kincora press release July 25th, 2024 6 Inflection Resources provides drilling update from Phase 1 Exploration Program in NSW - Inflection press release July 30th, 2024 7 Kincora secures strategic license in Australia's leading porphyry belt - Kincora press release November 21, 20198 ANT geophysics defines additional epithermal-porphyry targets at Spur Project - Waratah press release May 23, 20249 Reimaging porphyry copper exploration using Exosphere: Ambient Noise Tomography from the Duck Creek project, Macquarie Fleet and Inflection Case Study 2023 10 Completes 1,800Km2 Ambient Noise Tomography Survey Across Portfolio of Projects in New South Wales - Inflection press release July 10, 2024This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office 400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Fax: 1.888.241.5996Subsidiary office AustraliaVista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205Qualified PersonThe scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101.JORC Competent Person StatementInformation in this announcement that relates to Exploration Results, Mineral Resources or Ore Reserves are those that have been previously reported (with the original release referred to in this announcement), in the case of Mineral Resources or Ore Reserves the material assumptions and technical parameters underpinning the estimates have not materially changed, and have been reviewed and approved by Paul Cromie, who is a Competent Person under the definition established by JORC and has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The review and verification process for the information disclosed herein for the Nyngan Projects have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219846 Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-15

Modern DevOps Melbourne 2024 Partners with ACN Newswire; Offers Exclusive Discount

MELBOURNE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Mark your calendars for an unmissable event! We are thrilled to announce our partnership with the upcoming Modern DevOps Melbourne, taking place on October 8, 2024, at the prestigious Grand Hyatt Melbourne. This event promises to be a cornerstone for industry leaders and innovators in the DevOps community.Join us at Corinium's Modern DevOps Melbourne 2024, where you will have the opportunity to transform your DevOps delivery and explore revolutionary realms of platform engineering, DevSecOps, AI, and ModelOps. This is your chance to gain an unparalleled competitive edge in the ever-evolving tech landscape.We are extending a special invitation to all ACN Newswire via SeaPRwire.com readers, offering an exclusive discount code to join this invaluable industry gathering. Don't miss the chance to find inspiration, build new connections, and be part of a transformative experience.Get an exclusive $500 off the regular price by entering discount code DEVOPSPAR500 at checkout when registering.Keynote Speakers Include:Tim Baird, Senior Manager - DevOps, AIAMathangi VijayShankar, Engineering Lead API, MedibankAndrew Cunningham, Application Development & DevSecOps Team Lead, Australian Red Cross LifebloodJack Latrobe, Enterprise Architect – Sustainability External Relations & Legal, TelstraSerge Ambrose, Digital Technology Head – APAC, MMG LimitedAya Omar, Senior Manager Quality Engineering, WestpacParidhi Jha, Principal Machine Learning Engineer, Wesfarmers OneDigitalDave Lemphers, CTO, EasyGoNimisha Balyan, Chapter Lead, TelstraShivansh Sharma, Senior Manager Engineering - Platform & Reliability, TabcorpPouya Ghotbi, Security Lead APJ, AWSOlga Mirensky, Senior Platform Engineer, ANZNigel Fernandes, VP/GM Engineering (Ecosystem, Cloud, Platforms, Identity), XeroSean Duxbury, Principal Engineer – Google Cloud Platform, IAGDarragh Kennedy, Director of Engineering, ZendeskMichael Fornaro, Lead Cloud Engineer, ANZKey Themes at Modern DevOps Melbourne 2024:Maturing DevOps DNA: Elevate practices for greater efficiency and innovation in the software development lifecycle.Advance Your Toolchain with Automation, AI, and ML: Enhance scalability and efficiency in IT delivery.Bridging Legacy to Cloud: Unlock agility, scalability, and efficiency in modern DevOps practices.Unleash DevSecOps: Seamlessly integrate security measures into DevOps workflows.From Pipelines to Possibilities: Maximize the potential of CI/CD and deployment pipelines for DevOps velocity.This is an unparalleled opportunity to turbocharge scalable and secure DevOps deployment while aligning cyber and business strategies from a high-level perspective. Don't miss out on this chance to be part of Modern DevOps Melbourne!Register today: https://bit.ly/4ci5VsxAbout Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.For more information, please contact Moira Ungerleider at moira.ungerleider@coriniumgroup.com.  Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-15

Egyptian Heritage and Palestinian Folklore Shine at Alamein Festival

Egyptian Folk Traditions Take Centre Stage at AlameinIconic Performances Celebrate Egyptian and Palestinian HeritageOpera Al Layla Al-Kabira and Reda Troupe Steal the ShowAL ALAMEIN CITY, EGYPT, Aug 15, 2024 - (ACN Newswire via SeaPRwire.com) - The second edition of Alamein Festival 2024 celebrated Egypt's diverse cultural identity, heritage, and folk traditions.Part of the iconic performances throughout the festivalThe festival, organized by the United Media Services (UMS) under the patronage of Dr. Ahmed Hano, the Egyptian Minister of Culture, featured performances from folkloric groups across Egypt, highlighting the country's rich artistic and musical diversity.The Arab Opera troupe, led by Mohamed Mostafa, presented performances based on famous Egyptian songs, plays, and films, reinterpreted with new musical arrangements, along with a segment for children featuring beloved songs.The Ismailia troupe paid tribute to the Suez Canal region's folklore with performances like "The Saayaden" and "Betghani l meen ya hamam," underscoring Ismailia's cultural richness and significant contribution to the festival's diversity.Key performances included those by the "El-Horria" or Freedom and Aswan Folk Arts teams. The Aswan team, led by Medhat Mahram, performed Nubian folkloric pieces such as "Al-Arajeed" and "Al-Najrashad," with musical interludes by artists Hamada Harby and Omar Mustafa. With its rich historical and cultural significance, Aswan was a prominent and fitting feature of the festival.The Freedom team, under Nasreldin Mohamed, performed distinct pieces from Alexandria, including the "Banat Bahry" dance and the "Alexandrian Wedding Procession." These performances vividly brought Alexandria's rich cultural heritage to life.Additionally, the Assiut City Folk Arts team showcased traditional performances from the Assiut governorate, including "Al-'Asaayah," "Al-Tahmilah," and the "Arouset El-Mawlid" dance. These performances reflected Assiut's diverse historical influences, encompassing the Pharaonic, Roman, Coptic, and Islamic periods.A standout moment of the festival was the presentation of "Opera Al Layla Al-Kabira," a piece celebrating Egyptian visual identity by depicting Mawlid festivities. This operetta, composed by the late Salah Jahin with music by Sayed Mekkawy, remains a cultural cornerstone of Egyptian heritage.The iconic Reda Troupe also took part, performing a vibrant array of Egyptian folkloric dances. Their performance added to the celebration of the diverse heritage of various governorates, including "Dhaheya," and "Al-Hejala,"Palestinian folklore was also celebrated, with a concert featuring singer Mohamed Mounir and Dina El-Wedidi. El-Wedidi performed the operetta "Ragieen" and the iconic song "Leve Palestina," accompanied by a Palestinian dance troupe that showcased traditional performances in Palestinian costumes. This segment was a powerful celebration of the shared cultural heritage between Egypt and Palestine, making the festival a symbol of regional cultural unity.The 2024 edition of the New Alamein Festival featured a variety of activities, including theatrical performances produced by renowned producers and starring famous stars and young artists, football matches featuring legends and star players, visits from Egyptian ministers, the launch of major investment initiatives and partnerships, and collaboration with the United Media Services, the founder and organizer of Alamein Festival.For more information, please visit the festival website: https://elalameinfestival.comContact InformationEman Salempress@30n.orgSOURCE: Alamein Festival Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-15

Solar District Cooling Group Berhad Signs Underwriting Agreement with Mercury Securities Sdn Bhd for Its IPO on the ACE Market of Bursa Malaysia Securities Berhad

KUALA LUMPUR, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Solar District Cooling Group Berhad ("SDCG") is pleased to announce that it has entered into an underwriting agreement with Mercury Securities Sdn Bhd (“Mercury Securities”) today for its upcoming initial public offering ("IPO") on the ACE Market of Bursa Malaysia Securities Berhad.1.Mr Chris Lai Ther Wei, Director, Head of Capital Markets, Mercury Securities 2.Ms Tan Tai Kim, Director, Corporate Finance, Mercury Securities 3.Mr Chew Sing Guan, Managing Director of Mercury Securities 4.Mr Edison Kong, Managing Director, Solar District Cooling Group 5.Ms Eileen Liuk, Executive Director, Solar District Cooling Group 6. Ms Sheryn Chow Suet Yim, Director, Corporate Finance, Mercury Securities [L-R]SDCG and its subsidiaries (“Group”) are principally involved in the provision and maintenance of building management systems (BMS), solar thermal solutions and energy saving services. The Group has a proven track record of enhancing energy efficiency across various sectors and strives to establish benchmarks in energy management and cost efficiency.The IPO involves the public issue of 118,670,000 new ordinary shares ("Issue Shares"), representing 28.00% of SDCG’s enlarged issued share capital of 423,822,460 ordinary shares upon its listing.The Issue Shares will be allocated in the following manner:Malaysian Public: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by the Malaysian public, with 50.00% set aside for Bumiputera investors.Eligible Persons: 21,192,000 Issue Shares representing 5.00% of the enlarged issued share capital for application by eligible directors, employees, and persons who have contributed to the Group’s success.Selected Investors: 76,286,000 Issue Shares representing 18.00% of the enlarged issued share capital made available by way of private placement to selected investors.Mercury Securities will underwrite all the 42,384,000 Issue Shares made available for application by the Malaysian public and eligible persons.Mr. Edison Kong, Managing Director of SDCG, expressed his enthusiasm for the IPO, stating, “Our listing will enhance our visibility and reputation in the market and enable our directors, employees, business partners, and public investors to participate in the growth and continued expansion of our business, increasing shareholder value. We would like to express our sincere gratitude to Mercury Securities for their support and confidence in our Group."He added, "This corporate milestone will help scale our Group to new heights by tapping new opportunities and responding to the evolving needs of our customers and market trends. We remain focused on providing innovative solutions that create value for our customers, striving to exceed their expectations.Mr. Chew Sing Guan, Managing Director of Mercury Securities said, "We are delighted to be the Principal Adviser, Sponsor, Sole Underwriter, and Sole Placement Agent for SDCG and to play a part in their new corporate journey as a listed company on the ACE Market of Bursa Malaysia Securities Berhad. The listing will enable SDCG to tap into the capital market for its growth and expansion plans in the future."1. Mr Chew Sing Guan, Managing Director of Mercury Securities 2. Mr Edison Kong, Managing Director, Solar District Cooling Group[L-R]ABOUT SOLAR DISTRICT COOLING GROUP BERHADSolar District Cooling Group Berhad (SDCG) and its subsidiaries (the “Group”) is an established services provider of energy-efficient building management and solar thermal systems in Malaysia. The Group specialises in the design, installation, and maintenance of BMS and solar thermal solutions, serving a diverse range of sectors including commercial, institutional, and industrial properties. With a commitment to sustainability and innovation, SDCG has earned a reputation for excellence in the building management system and solar thermal industries.For more information, visit www.sdc.myIssued By: Swan Consultancy Sdn Bhd on behalf of Solar District Cooling Group.For more information, please contact:Jazmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizWilliam YeoTel: +60 16-213 2103Email: w.yeo@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-15

มหาอำนาจน้ำมันตะวันออกกลางสั่งห้ามเรือ “กองเรือเงา” ของรัสเซียที่พยายามทำลายล้างมาตรการคว่ำบาตร

(SeaPRwire) -   สหรัฐอาหรับเอมิเรตส์ได้ต่อต้านความพยายามของรัสเซียที่จะใช้ "กองเรือเงา" โดยปฏิเสธไม่ให้เรือใด ๆ จากประเทศแอฟริกา Eswatini เข้าเทียบท่าในท่าเรือของตน"การใช้ 'กองเรือเงา' เพื่อลักลอบขนส่งน้ำมันในขณะที่ปกปิดแหล่งกำเนิด เพื่อหลีกเลี่ยงการคว่ำบาตรทางเศรษฐกิจของตะวันตก เป็นส่วนหนึ่งของกลยุทธ์การป้องกันการคว่ำบาตรของรัสเซีย" Rebekah Koffler อดีตเจ้าหน้าที่ข่าวกรอง DIA และผู้เขียน "Putin's Playbook" กล่าวกับ Digital"มอสโกคาดการณ์การคว่ำบาตรของสหรัฐฯ ก่อนหน้า " Koffler กล่าว "ดังนั้น ปูตินจึงได้ดำเนินการป้องกันการคว่ำบาตรของเศรษฐกิจรัสเซียด้วยมาตรการหลายอย่างตั้งแต่ปี 2014 เมื่อกองกำลังรัสเซียยึดครองไครเมีย""เรือที่ประกอบขึ้นเป็นกองเรือมืดนี้โดยทั่วไปมักจะเป็นเรือที่เก่าแก่ ขาดมาตรฐานความปลอดภัยที่เหมาะสม ขาดประกันภัย ดังนั้นจึงเป็นภัยคุกคามต่อความปลอดภัยทางทะเล เนื่องจากอาจสร้างสถานการณ์อันตรายได้ตลอดเวลา" เธอกล่าวเสริมรายชื่อเรือที่เผยแพร่โดยกระทรวงพลังงานและโครงสร้างพื้นฐานของสหรัฐอาหรับเอมิเรตส์ระบุว่า Eswatini เป็นประเทศล่าสุดที่ไม่ควรให้บริการใด ๆ จากตัวแทนเรือหรือ บริษัท ทางทะเลของสหรัฐอาหรับเอมิเรตส์ เนื่องจาก "พวกเขาไม่ได้ปฏิบัติตามประกาศนี้เพื่อหลีกเลี่ยงความรับผิดชอบทางกฎหมาย""...รัฐบาลนี้ได้ตัดสินใจที่จะรวมเรือที่จดทะเบียนภายใต้ธงของ Eswatini (สวาซิแลนด์) เข้าในรายการเรือธงรัฐที่ถูกจำกัดที่เข้ามาในน่านน้ำและท่าเรือของสหรัฐอาหรับเอมิเรตส์ เว้นแต่จะได้รับการจัดประเภทโดยสมาชิกของ IACS Class หรือโดย Emirates Classification Society" ประกาศดังกล่าวระบุธงของ Eswatini เริ่มปรากฏขึ้นในปีนี้ โดย Clarkson Research Services Ltd. บริษัทนายหน้าเรือรายงานว่าไม่มีเรือใดเลยในปี 2023 ที่จดทะเบียนภายใต้ธงของ Eswatini แม้ว่าจะมีเรือ 26 ลำที่แล่นอยู่ในทะเลEswatini เป็นประเทศที่ไม่มีทางออกสู่ทะเลในแอฟริกาใต้ และได้ทำงานร่วมกับรัสเซียมากขึ้นเพื่อขนส่งน้ำมันเป็นส่วนหนึ่งของการหลีกเลี่ยงการคว่ำบาตร ของเรือธง Eswatini 18 ลำในข้อมูลการติดตามเรือ พบว่า 16 ลำมีเจ้าของ "ไม่ชัดเจน" แต่เรือบรรทุกน้ำมันหลายลำขนส่งน้ำมันที่ผลิตในรัสเซียและอิหร่านสหรัฐอเมริกาคว่ำบาตรเรือ Eswatini สามลำเนื่องจากสนับสนุนระบอบการปกครองของประธานาธิบดีบาชาร์ อัล-อัสซาดของซีเรีย และต่อมาช่วยส่งออกธัญพืชจากพื้นที่ที่รัสเซียยึดครองในยูเครนในช่วงที่การขนส่งธัญพืชได้รับการเจรจาโฆษกของทะเบียนเรือ Eswatini กล่าวกับทางออกว่าประเทศดังกล่าวได้ถอดชื่อเรือสองลำออกเนื่องจากละเมิดแนวทางปฏิบัติของประเทศในเรื่องของการปฏิบัติตามกฎระเบียบ แต่หนึ่งเดือนต่อมา เรือสองลำยังคงใช้ธง Eswatini โฆษกโต้แย้งว่าเมื่อประเทศถอดชื่อเรือออก พวกเขาจะหยุดติดตามเรือเหล่านั้น และการใช้ธงใด ๆ ก็ "ผิดกฎหมายและไม่ถูกต้อง"Atlantic Council องค์กรวิจัยในเดือนมกราคมเกี่ยวกับ "กองเรือมืด" ของรัสเซียที่กำลังเติบโต ประมาณว่ามีเรือ 1,400 ลำที่ประกอบขึ้นเป็นกองเรือและปฏิบัติงานใน "เขตสีเทา" ซึ่งทำให้ประเทศต่างๆ ยากที่จะลงโทษความกังวลอย่างยิ่งดังที่ทั้ง Koffler และ Atlantic Council ตั้งข้อสังเกต เน้นไปที่สภาพที่ย่ำแย่ของเรือเหล่านี้ เนื่องจากพวกมันปฏิบัติการอย่างผิดกฎหมายและไม่ต้องการดึงดูดความสงสัยจากเจ้าหน้าที่องค์กรวิจัยเรียกเรือดังกล่าวว่า "เก่าและดูแลรักษาไม่ดี" ซึ่งทำให้เกิดเหตุการณ์ที่เรือที่ถูกต้องต้องจ่ายเงิน เนื่องจากกองเรือเงาไม่มีประกันภัยที่เหมาะสมซึ่งเป็นภาระของประเทศชายฝั่งทะเล ซึ่งมีหน้าที่ตามอนุสัญญาการค้นหาและช่วยเหลือที่จะใช้เวลาและทรัพยากรในการช่วยเหลือเรือผิดกฎหมายที่ประสบภัยโดยไม่มีการเยียวยา"ความเสียหายที่อาจเกิดขึ้นกับรัฐชายฝั่งทะเลนั้นจับต้องได้ แต่เนื่องจากการรุกรานไม่ได้เกี่ยวข้องกับทางทหาร จึงหมายความว่าประเทศต่างๆ แทบจะเป็นไปไม่ได้เลยที่จะแก้แค้นความเสียหายที่เกิดจากเรือเงา แม้ว่าจะสามารถพิสูจน์ได้ว่าเรือลำดังกล่าวขนส่งสินค้าของรัสเซีย" Elisabeth Braw นักวิชาการอาวุโสของ Atlantic Council เขียนบทความนี้ให้บริการโดยผู้ให้บริการเนื้อหาภายนอก SeaPRwire (https://www.seaprwire.com/) ไม่ได้ให้การรับประกันหรือแถลงการณ์ใดๆ ที่เกี่ยวข้องกับบทความนี้ หมวดหมู่: ข่าวสําคัญ ข่าวประจําวัน SeaPRwire จัดส่งข่าวประชาสัมพันธ์สดให้กับบริษัทและสถาบัน โดยมียอดการเข้าถึงสื่อกว่า 6,500 แห่ง 86,000 บรรณาธิการและนักข่าว และเดสก์ท็อปอาชีพ 3.5 ล้านเครื่องทั่ว 90 ประเทศ SeaPRwire รองรับการเผยแพร่ข่าวประชาสัมพันธ์เป็นภาษาอังกฤษ เกาหลี ญี่ปุ่น อาหรับ จีนตัวย่อ จีนตัวเต็ม เวียดนาม ไทย อินโดนีเซีย มาเลเซีย เยอรมัน รัสเซีย ฝรั่งเศส สเปน โปรตุเกส และภาษาอื่นๆ 

2024-08-15

ธนาคารอาหารนิวซีแลนด์แจกยาไอซ์ผิดพลาด ปนอยู่ในขนม คาดว่าเป็นอันตรายถึงชีวิต

(SeaPRwire) -   องค์กรการกุศลที่ทำงานกับคนไร้บ้านได้แจกจ่ายขนมที่บรรจุยาเมทแอมเฟตามีนในปริมาณที่อาจถึงแก่ชีวิตโดยไม่รู้ตัว ในถุงอาหารหลังจากที่ได้รับบริจาคจากประชาชนเมื่อวันพุธที่ผ่านมา Auckland City Mission กล่าวว่าเจ้าหน้าที่ได้เริ่มติดต่อบุคคลประมาณ 400 คนเพื่อติดตามหาถุงอาหารที่อาจบรรจุขนมเหล่านี้ ซึ่งเป็นก้อนเมทแอมเฟตามีนแข็งห่อด้วยซองขนม ทางการนิวซีแลนด์กล่าวว่ามีผู้ได้รับการรักษาในโรงพยาบาล 3 คนหลังจากรับประทานขนมเหล่านี้ แต่ต่อมาได้รับการปล่อยตัวตามข้อมูลจาก New Zealand Drug Foundation ซึ่งเป็นองค์กรตรวจสอบยาและนโยบาย ซึ่งเป็นผู้ทดสอบขนมเหล่านี้เป็นครั้งแรก ปริมาณเมทแอมเฟตามีนในแต่ละขนมนั้นสูงกว่าระดับที่ผู้คนมักจะทานถึง 300 เท่า และอาจถึงแก่ชีวิตได้เบน เบิร์กส แอง โฆษกของมูลนิธิ กล่าวว่า การปลอมแปลงเป็นสินค้าที่ไม่มีพิษภัยเป็นเทคนิคการลักลอบขนส่งข้ามชายแดนที่พบได้บ่อย และอาจมีการแจกจ่ายขนมเหล่านี้ในนิวซีแลนด์มากขึ้นเบิร์กส แอง กล่าวว่า ขนมเหล่านี้มีมูลค่าสูงถึง 608 ดอลลาร์ต่อชิ้น ซึ่งบ่งชี้ว่าการบริจาคโดยบุคคลที่ไม่ทราบชื่ออาจเกิดจากความผิดพลาดมากกว่าการโจมตีโดยเจตนาผู้ตรวจการตำรวจ เกล็นน์ บอลด์วิน กล่าวว่า "ความคิดเห็นเบื้องต้น" ของเจ้าหน้าที่คือ เหตุการณ์นี้น่าจะเป็นโครงการนำเข้าที่ผิดพลาด แต่ลักษณะและขนาดของการดำเนินการยังไม่ทราบแน่ชัด เจ้าหน้าที่ได้ยึดขนมเหล่านี้ได้ 16 ชิ้น แต่ไม่ทราบว่ามีขนมเหล่านี้หมุนเวียนอยู่ในตลาดกี่ชิ้นเฮเลน โรบินสัน ผู้บริหาร City Mission กล่าวว่า ตั้งแต่วันอังคารที่ผ่านมา มีครอบครัว 8 ครอบครัว รวมถึงเด็กอย่างน้อยหนึ่งคน รายงานว่าบริโภคขนมที่ปนเปื้อน รสชาติที่ "น่ารังเกียจ" ทำให้ส่วนใหญ่พ่นออกมาทันทีโรบินสัน กล่าวว่า ธนาคารอาหารขององค์กรการกุศลนี้รับเฉพาะอาหารที่ผลิตในเชิงพาณิชย์ในบรรจุภัณฑ์ปิดผนึก ขนมสับปะรดที่มีตราสินค้า Rinda ของมาเลเซีย "ดูเหมือนขนมเมื่อได้รับบริจาค" มาในถุงขนาดขายปลีก เธอกล่าวเสริมเมื่อวันอังคารที่ผ่านมา Auckland City Mission ได้รับแจ้งจากลูกค้าธนาคารอาหารซึ่งรายงานว่าขนม "มีรสชาติแปลก ๆ" พนักงานได้ลองชิมขนมที่เหลืออยู่บางส่วนและติดต่อเจ้าหน้าที่ทันที บอลด์วิน กล่าวว่า พนักงานคนหนึ่งถูกนำตัวส่งโรงพยาบาลหลังจากลองชิมขนม เด็กและ "วัยรุ่น" ก็ได้รับการรักษาในโรงพยาบาลเช่นกันก่อนที่จะได้รับการปล่อยตัวโรบินสัน กล่าวว่า ขนมเหล่านี้ถูกบริจาคเมื่อประมาณ 6 สัปดาห์ที่ผ่านมา ไม่แน่ชัดว่ามีการแจกจ่ายไปแล้วกี่ชิ้นและมีกี่ชิ้นที่ทำจากเมทแอมเฟตามีนRinda กล่าวในแถลงการณ์เป็นลายลักษณ์อักษรว่า บริษัทได้ทราบจากข่าวในนิวซีแลนด์ว่าขนมของตน "อาจถูกนำไปใช้ในทางที่ผิด" และจะให้ความร่วมมือ"เราต้องการชี้แจงว่า Rinda Food Industries ไม่ได้ใช้หรือสนับสนุนการใช้ยาเสพติดที่ผิดกฎหมายใด ๆ ในผลิตภัณฑ์ของเรา" สตีเวน เทห์ ผู้จัดการทั่วไปกล่าวเมทแอมเฟตามีนเป็นสารกระตุ้นที่มีฤทธิ์รุนแรงและเสพติดสูง ซึ่งส่งผลต่อระบบประสาทส่วนกลาง มีรูปร่างเป็นผงผลึกสีขาว ไม่มีกลิ่น รสขม ละลายในน้ำหรือแอลกอฮอล์ได้ง่ายบทความนี้ให้บริการโดยผู้ให้บริการเนื้อหาภายนอก SeaPRwire (https://www.seaprwire.com/) ไม่ได้ให้การรับประกันหรือแถลงการณ์ใดๆ ที่เกี่ยวข้องกับบทความนี้ หมวดหมู่: ข่าวสําคัญ ข่าวประจําวัน SeaPRwire จัดส่งข่าวประชาสัมพันธ์สดให้กับบริษัทและสถาบัน โดยมียอดการเข้าถึงสื่อกว่า 6,500 แห่ง 86,000 บรรณาธิการและนักข่าว และเดสก์ท็อปอาชีพ 3.5 ล้านเครื่องทั่ว 90 ประเทศ SeaPRwire รองรับการเผยแพร่ข่าวประชาสัมพันธ์เป็นภาษาอังกฤษ เกาหลี ญี่ปุ่น อาหรับ จีนตัวย่อ จีนตัวเต็ม เวียดนาม ไทย อินโดนีเซีย มาเลเซีย เยอรมัน รัสเซีย ฝรั่งเศส สเปน โปรตุเกส และภาษาอื่นๆ 

2024-08-15

Kess Energy – Kess Energy Chairman Announces Purchase of 200,000 Shares

Brasilia, Brazil – August 14, 2024 – (SeaPRwire) – Kess Energy, a leading junior lithium mining company, is pleased to announce that its Chairman, Inato Ramirez, has purchased 200,000 shares of Kess Energy, further demonstrating his confidence in the company’s future growth and its commitment to delivering value to stakeholders. Strengthening Leadership Commitment The purchase of 200,000 shares by Mr. Ramirez serves to reiterate his strong belief in Kess Energy’s strategic direction and the significant potential of its lithium projects. This investment aligns the Chairman’s interests with those of the company’s stakeholders and signals robust confidence in Kess Energy’s long-term prospects. Chairman’s Statement “I am excited about the future of Kess Energy and our role in driving the global transition to sustainable energy,” said Mr. Ramirez. “This personal investment reflects my full confidence in our team, our assets, and our ability to execute our growth strategy. I am committed to ensuring that we continue to deliver exceptional value to our stakeholders.” Company Vision and Growth Strategy Kess Energy is at the forefront of the lithium industry, focusing on sustainable mining practices and innovation in the South American “lithium triangle”. The company’s strategic initiatives include expanding its lithium production capacity, advancing exploration projects, and forging partnerships to support the burgeoning demand for lithium in electric vehicles and renewable energy storage. About Kess Energy Kess Energy is a junior lithium mining company dedicated to meeting the increasing global demand for lithium through responsible and sustainable mining practices that respect and consider the needs of the communities in which its assets are located. With a portfolio of high-quality lithium assets and a commitment to innovation, Kess Energy is well-positioned to play a pivotal role in the energy transition while enabling communities to share in the commercial benefits of its business.. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations and projections about future events and are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements due to various factors. Know more please contact Phone No.: +55 61 4042 9257, or visit our office at: Centro Empresarial Varig SCN QUADRA 04 BL B – Asa Norte, Brasília – DF, 70714-900, Brazil. Media Contact Brand: Kess Energy Contact: Joseph Hera Email: contact@kessenergy.com Website: https://kessenergy.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

2024-08-14

Dr.Friend Puppy, Exhibits at Global Pet Show, Targeting Overseas Markets

Seoul, Korea – August 14, 2024 – (SeaPRwire) -The premium sleep and healthcare brand Dr.Friend’s pet sleep care product, Dr.Friend Puppy (owned by World Home Doctor Corp.), will be actively targeting overseas markets from the second half of the year. Dr.Friend Puppy will participate in the SUPER ZOO in Las Vegas, USA from August 14-16 to actively promote Dr.Friend’s unique sleep & healthcare technology. SUPER ZOO is one of the most established and prestigious pet industry trade shows in North America. It has been held since 1950, and it is considered the largest pet industry show in North America. It continues to be one of the most productive and vibrant shows yearly. Following CES2024 in January and IHS2024 in March, Dr.Friend Puppy will participate in Super Zoo to introduce its unique pet sleep care technology and pet humanization philosophy to pet industry stakeholders around the world. In particular, Dr.Friend Puppy is a pet-specific sleep care product that incorporates Dr.Friend’s sleep care technology, such as grounding technology and natural material technology. This has the advantage of harmonizing the natural characteristics of pets that are healthiest when they are in nature with the characteristics of their living environment. Dr.Friend’s core natural functional material technologies, such as charcoal wool with antibacterial properties and natural wool, are optimally proportioned to enhance pet sleep care without using chemicals such as memory foam, so pets can feel comfortable and stable sleeping environments every day. In addition, a water-repellent technology that coats a thin film on top of the fabric tissue is also applied to prevent contaminants that may occur due to the nature of the pet’s living environment from penetrating the surface of the fabric, making it more hygienic and convenient to use. By compensating for the disadvantage of sharing the same living environment as the owner, such as an apartment, pet grounding allows pets to get enough natural interaction in the comfort of their home. Dr.Friend will highlight various uniqueness and differentiation of Dr.Friend Puppy, such as realizing the value of pet humanization to ultimately maintain health, prevent various diseases, and reduce medical costs. “Dr.Friend’s grounding and natural material technology continues to gain scientific credibility through anti-inflammatory and stress relief studies that we have been conducting since 2018,” said Kim Ji Youn, CEO of Dr.Friend, who is participating in the exhibition. “In particular, the stress relief effect paper published in Biomedicines, an SCI-level journal, is showing high interest among animal healthcare professionals such as US veterinarians.” She also said, “As we are currently discussing clinical trials with domestic and foreign medical organizations to help improve pets’ health, we will actively promote the advantages of our sleep care technology and healthcare principles to expand cooperation opportunities with various buyers and partners.” After the Super Zoo exhibition, Dr.Friend Puppy will also participate in Pet Fair Asia, August 21-25 in Shanghai, China, expanding its growth strategy to the Asia Pacific region. Pet Fair Asia is Asia’s largest international pet products exhibition, and along with the Super Zoo, it is one of the world’s largest and most influential pet shows. This year’s event will be the largest since its inception in 1997, and Dr.Friend will present its authentic sleep &healthcare value and technology to more than 100,000 buyers and visitors, exploring opportunities to expand sales and establish strategic partnerships. About Dr. Friend Dr. Friend is a sleep care functional bedding brand that combines ergonomic functions and premium materials. It was created through continuous research and development for a long period of time to realize a safe and stable sleeping environment and to satisfy customers at all times. Media Contact Brand: Dr.Friend Puppy (World Home Doctor Corp.) Contact : Chon GyeongUn Email: cgu0823@worldhomedr.com Phone: +8210-4981-6360 Website: https://worldhome.global/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

2024-08-14

C14 Enters into Partnership with Tune.FM

New York, NY – August 14, 2024 – (SeaPRwire) – C14, a leading provider of fiat-to-crypto on and off-ramp solutions, has joined forces with Tune.FM, a cutting-edge music NFT trading platform, to release an off-ramp solution for JAM, the native token of the Tune.fm application. This collaboration marks a significant step forward in the integration of cryptocurrency with the music industry, providing users with seamless conversion of JAM tokens to fiat currency. Tune.fm is a revolutionary platform where artists and fans can trade music NFTs, unlocking new revenue streams and interactive experiences in the music ecosystem. The native token, JAM, is at the heart of Tune.fm’s economy, facilitating transactions and rewarding artists and fans alike. With the introduction of an off-ramp solution, users will now have the ability to convert JAM tokens into fiat currency, enhancing the platform’s usability and accessibility. This partnership deepens C14 and Tune.fm’s existing relationship, where C14 provides on-ramping services for Tune.fm’s existing base of over TK users. C14 provides ramping services for JAM for users in over two dozen countries. JAM is built on the Hedera Hashgraph, a low cost, high throughput distributed ledger technology. C14 has established itself as a trusted partner in the crypto space, offering robust solutions that bridge the traditional financial system with the digital asset world. The off-ramp for JAM tokens leverages C14’s secure and efficient infrastructure, ensuring a smooth and reliable conversion process. C14 and Tune.FM will roll out service for users in the United States versus ACH first, with instant SEPA payouts to the European Union following soon after. Key Benefits of the Collaboration Seamless Conversion: Users can easily convert their JAM tokens into fiat currency, broadening the utility and acceptance of JAM in the real world. Enhanced Accessibility: The off-ramp solution lowers the barriers for new users to engage with Tune.FM, providing a straightforward method to cash out their JAM tokens. Security and Trust: C14’s proven track record in the industry ensures a safe and compliant process for all transactions, instilling confidence in users. “Partnering with Tune.fm aligns perfectly with our mission to make crypto accessible to everyone,” said Erich Grant, CEO of C14. “We are excited to support the vibrant community of artists and fans on Tune.fm by providing an easy and secure way to convert JAM tokens to fiat currency.” “This collaboration with C14 is a game-changer for our platform,” added Andrew Antar, CEO of Tune.FM. “The off-ramp solution not only enhances the user experience but also paves the way for wider adoption of JAM tokens in the mainstream economy.” The off-ramp for JAM tokens is expected to be available to Tune.FM users starting July 25th For more information on how to use the off-ramp, visit Tune.FM. About C14 C14 is a leading provider of fiat-to-crypto on and off-ramp solutions, dedicated to bridging the gap between traditional finance and the digital asset economy. With a focus on security, compliance, and user experience, C14 offers seamless conversion services that empower users to interact with the crypto world effortlessly. To know more please contact +1 (845) 366-6902. About Tune.FM Tune.fm is a pioneering music NFT trading platform that empowers artists and fans to engage in a vibrant digital music economy. By leveraging blockchain technology and the JAM token, Tune.FM enables transparent and rewarding interactions within the music industry, fostering a new era of music ownership and distribution. Media Contacts Erich Grant, Founder of C14 erich@c14.money Website: https://c14.money/ Andrew Antar, Founder of Tune.FM hello@Tune.FM Website: http://tune.fm/ The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...

2024-08-14

Experience Eternal Romance with Exquisite Blue Diamonds

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection -  Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection -  Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your gentleness is my greatest safeguard in this life. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection -  Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection -  Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection -  Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6992 2589Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-14

Valuufy Established to Transform Sustainable Business and Investing

KYOTO, JAPAN, Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully transparent and actionable framework for assessing and improving sustainability performance.The current state of sustainability reporting:·  Confusing and inefficient for companies·  Multiple different standards and metric·  Emphasis on past activities rather than future strategies·  Difficult to capture real impacts on people and the environment·  No reliable benchmark for investors to assess sustainability risks and opportunitiesValuuCompass addresses precisely these challenges.The ValuuCompass addresses a critical gap in the market: the lack of a holistic, transparent system for assessing a company's true stakeholder impacts and sustainability risks that arise from these. At the heart of this new product is the Value Model, which has synthesized more than 1,200 individual impact measurements from leading global ESG and sustainability frameworks into a clear goal-based model to measure stakeholder impacts and value creation. With this new assessment system, Valuufy offers businesses and investors a clear, actionable view of value creation that goes far beyond traditional sustainability and ESG metrics. "In an era where 'value washing' - the pretence of sustainable value creation - poses significant financial and reputational risks, both companies and investors need a reliable compass," said Kyle Barnes, CEO of Valuufy. "Valuufy's products and services provide these capabilities, offering a level of transparency and insight that goes beyond all other existing solutions."Dr. Philip Sugai, Director of Research at Valuufy and Director at the Value Research Center, emphasized the revolutionary approach that Valuufy is taking: "The current systems underlying sustainability and ESG are fundamentally broken, focusing on backwards-looking disclosures rather than forward-looking strategies.  Valuufy was established to change this paradigm, helping businesses to shift their focus to creating real, and measurable value across their key stakeholders."Valuufy’s ongoing activities aim to bring this important mindset to business strategy creation for businesses of all sizes. "Today, we're not just launching a new tool; we're setting a new standard for sustainable business and investing," added Marco Koeder, Chief Marketing Officer. By 2030, we aim to establish the Value Model as the global benchmark for measuring and creating sustainable value."Benefits of ValuuCompass for Companies:·  First universal, objective standard to measure real impact on people and the planet·  Provides actionable recommendations for improvement·  Enhances performance in the sustainability reporting framework·  Transforms complex data into clear, strategic insightsBenefits of ValuuCompass for Investors:·  Enables truly informed decisions on sustainability risks and opportunities·  Offers rigorous, quantifiable metrics for portfolio assessment·  Aligns perfectly with the financial sector's data-driven approach·  Provides a competitive edge in sustainable investingDiscover how Valuufy is revolutionizing the future of sustainability at www.valuufy.com.About ValuufyValuufy Inc seeks to transform how the world understands and acts on sustainability. Founded in 2024, Valuufy is a registered Japanese startup in Kyoto, Japan, born of 10 years of academic value research at Doshisha University and the Value Research Center. Led by an international team with expertise in value research, sustainability strategies, innovative technologies, business development, and ESG assessments, Valuufy provides a suite of products and services to promote value-creation activities across stakeholders for businesses of all sizes - to set new standards in transparent, data-driven decision-making in the realm of sustainability and value creation. For more, visit www.valuufy.com.The Value Research Center was officially established at Doshisha University in Kyoto, Japan, in November 2021 to develop a system for measuring, monitoring, assessing, and reporting on organizations' value creation and destruction impacts on various stakeholder groups. The result is the Value Model, which forms the foundation for ValuuCompass.Contact:Press/MediaE: news@valuufy.comT: +81-90-9742-0860Marco KoederE: marco@valuufy.com T: +49-175-999-8647 Copyright 2024 JCN Newswire via SeaPRwire.com.

2024-08-14

“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2) In the UAE, it is reported that 4.09% of those over 60 years old have dementia.(3) AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.(4)Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(5) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(6) About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the LEQEMBI group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the LEQEMBI group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong and Israel for the treatment of MCI due to AD and mild AD dementia. Eisai has also submitted applications for approval of LEQEMBI in 11 countries and regions. A supplemental Biologics License Application (sBLA) for intravenous maintenance dosing was submitted to the U.S. Food and Drug Administration (FDA) in March 2024, which was accepted in June 2024. The rolling submission of a Biologics License Application (BLA) for maintenance dosing of a subcutaneous injection formulation, which is being developed to enhance convenience for patients, was initiated in the U.S. under Fast Track status in May 2024.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai, Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S), LinkedIn (for global, U.S. and EMEA) and Facebook (global).About BiogenFounded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTubeReferences(1) Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease at Clinical Trials on Alzheimer's Disease (CTAD) conference. Available at: https://www.eisai.co.jp/news/2022/news202285.html.(2) van Dyck, H., et al. Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 2023;388:9-21. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948.(3) Qassem T., et al, Prevalence and economic burden of dementia in the Arab world. BJPsych Open. 2023 Jul; 9(4): e126. https://doi.org/10.1192%2Fbjo.2023.517. (4) World Health Organization. Dementia Fact Sheet. March 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/dementia.(5) Amin L, Harris DA. Aβ receptors specifically recognize molecular features displayed by fibril ends and neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z(6) Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Biogen Safe HarborThis news release contains forward-looking statements, about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including  lecanemab; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "potential," "will," "would" and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements.These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation unexpected concerns that may arise from additional data, analysis or results obtained during clinical studies; the occurrence of adverse safety events; risks of unexpected costs or delays; the risk of other unexpected hurdles; regulatory submissions may take longer or be more difficult to complete than expected; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of Biogen's drug candidates, including lecanemab; actual timing and content of submissions to and decisions made by the regulatory authorities regarding lecanemab; uncertainty of success in the development and potential commercialization of lecanemab; failure to protect and enforce Biogen's data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and third party collaboration risks, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen's expectations in any forward-looking statement. Investors should consider this cautionary statement as well as the risk factors identified in Biogen's most recent annual or quarterly report and in other reports Biogen has filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this news release. Biogen does not undertake any obligation to publicly update any forward-looking statements.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Biogen Inc.Jack Cox+ 1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Chuck Triano+ 1-781-464-2442IR@biogen.com Copyright 2024 JCN Newswire via SeaPRwire.com.

2024-08-14

นักบินเสียชีวิตหลังจากเฮลิคอปเตอร์ตกบนหลังคาโรงแรมในออสเตรเลียระหว่างเที่ยวบินที่ไม่ได้รับอนุญาต

(SeaPRwire) -   นักบินเฮลิคอปเตอร์เสียชีวิตและมีผู้ได้รับบาดเจ็บในช่วงเช้าวันจันทร์หลังจากนักบินชนเฮลิคอปเตอร์ลงบนหลังคาโรงแรมในออสเตรเลียระหว่างเที่ยวบินที่ไม่ได้รับอนุญาต เจ้าหน้าที่กล่าวNew Zealand Herald ระบุชื่อนักบินคือเบลก วิลสัน วัย 23 ปี จาก . บริษัทการบิน Nautilus Aviation ยืนยันกับสำนักข่าวว่า วิลสันเป็นพนักงานของบริษัท แต่ไม่เคยบินในออสเตรเลียมาก่อนบริษัทกล่าวว่าเขาเป็นสมาชิกของทีมภาคพื้นดินและได้รับใบอนุญาตนักบินเฮลิคอปเตอร์ในนิวซีแลนด์ แต่ไม่ได้รับอนุญาตให้บินเฮลิคอปเตอร์ของบริษัทในออสเตรเลียชายคนนี้ทำงานกับ Nautilus Aviation มาเป็นเวลา 4 เดือน และเพิ่งได้รับการเลื่อนตำแหน่งให้เป็นงานภาคพื้นดินที่ฐานอื่นของบริษัท Nautilus Aviation กล่าว ก่อน , ชายคนนี้ได้เข้าร่วมงานสังคมกับเพื่อนร่วมงานเพื่อเฉลิมฉลองการย้ายไปยังตำแหน่งใหม่ บริษัทกล่าวเที่ยวบินดังกล่าวไม่ได้รับอนุญาตและเฮลิคอปเตอร์ "ถูกนำไปใช้ในทางที่ผิด" บริษัทกล่าวเสริมอุบัติเหตุในช่วงเช้าตรู่ของวันจันทร์ส่งผลให้ต้องอพยพผู้คนหลายร้อยคนออกจากอาคารเนื่องจากเปลวเพลิงลุกไหม้เครื่องบินคู่รักที่พักอยู่ในโรงแรมถูกนำส่งโรงพยาบาลเนื่องจากสูดดมควัน และทั้งสองคนได้รับการปล่อยตัวแล้ว พันตำรวจโทแชน โฮล์มส์ หัวหน้าหน่วยปฏิบัติการของหน่วยบริการกล่าวกับผู้สื่อข่าว ไม่มีใครได้รับบาดเจ็บบนพื้นดินริชาร์ด บาร์เกอร์ ซีอีโอของสนามบินเคิร์นส์ กล่าวว่าผลการตรวจสอบเบื้องต้นในวันจันทร์แสดงให้เห็นว่า "ไม่มีการละเมิดโปรแกรมหรือกระบวนการรักษาความปลอดภัยของสนามบิน"สนามบินดำเนินงานภายใต้ "โปรแกรมความปลอดภัยการขนส่งหลายระดับที่ได้รับการรับรองจากรัฐบาลกลาง" บาร์เกอร์กล่าวอุบัติเหตุเกิดขึ้นในย่านท่องเที่ยวที่คึกคักของเคิร์นส์ เมืองเขตร้อนที่มีประชากร 150,000 คนทางตอนเหนือของควีนส์แลนด์ ซึ่งเป็นช่วงฤดูท่องเที่ยวพยานกล่าวกับสำนักข่าวท้องถิ่นว่าเสียงดังของอุบัติเหตุเหมือนกับระเบิดควันพวยพุ่งและเปลวเพลิงลุกขึ้นจากหลังคาของ DoubleTree Hilton และใบพัดของเฮลิคอปเตอร์หนึ่งใบตกลงไปในสระว่ายน้ำของโรงแรม เครือข่ายโทรทัศน์ออสเตรเลีย ABC รายงานโรงแรมยังคงปิดล้อมขณะที่กำลังตรวจสอบความแข็งแรงของโครงสร้าง ดิจิตอลได้ติดต่อ Nautilus Aviation และตำรวจรัฐควีนส์แลนด์เพื่อขอข้อมูลอัปเดตบทความนี้ให้บริการโดยผู้ให้บริการเนื้อหาภายนอก SeaPRwire (https://www.seaprwire.com/) ไม่ได้ให้การรับประกันหรือแถลงการณ์ใดๆ ที่เกี่ยวข้องกับบทความนี้ หมวดหมู่: ข่าวสําคัญ ข่าวประจําวัน SeaPRwire จัดส่งข่าวประชาสัมพันธ์สดให้กับบริษัทและสถาบัน โดยมียอดการเข้าถึงสื่อกว่า 6,500 แห่ง 86,000 บรรณาธิการและนักข่าว และเดสก์ท็อปอาชีพ 3.5 ล้านเครื่องทั่ว 90 ประเทศ SeaPRwire รองรับการเผยแพร่ข่าวประชาสัมพันธ์เป็นภาษาอังกฤษ เกาหลี ญี่ปุ่น อาหรับ จีนตัวย่อ จีนตัวเต็ม เวียดนาม ไทย อินโดนีเซีย มาเลเซีย เยอรมัน รัสเซีย ฝรั่งเศส สเปน โปรตุเกส และภาษาอื่นๆ 

2024-08-14

บลิงเคนเลื่อนการเยือนตะวันออกกลางเนื่องจากความกังวลด้านความปลอดภัย คาดหวังการตอบโต้จากอิหร่าน

(SeaPRwire) -   รายงานว่า นายแอนโทนี บลิงเคน รัฐมนตรีต่างประเทศสหรัฐฯ ได้เลื่อนการเดินทางไปยัง เนื่องจากมีความกังวลด้านความปลอดภัยที่เพิ่มขึ้นในภูมิภาค และการโจมตีตอบโต้ที่อาจเกิดขึ้นจากอิหร่านต่ออิสราเอล ตามรายงานของ Axios โดยอ้างอิงแหล่งข่าวที่ไม่เปิดเผยชื่อสองราย การเดินทางของบลิงเคนซึ่งเดิมกำหนดไว้ในวันอังคาร ถูกเลื่อนออกไปเนื่องจาก "ความไม่แน่นอนเกี่ยวกับสถานการณ์" การเลื่อนการเดินทางเกิดขึ้นก่อนการเจรจาหยุดยิงที่วางแผนไว้ในสัปดาห์นี้ หลังจากการสู้รบระหว่างอิสราเอลกับ ในฉนวนกาซามาานานกว่า 10 เดือน เมื่อวันอังคารที่ผ่านมา ยิงจรวดสองลูกมุ่งเป้าไปที่เทลอาวีฟ ขณะที่อิสราเอลโจมตีทางอากาศอย่างร้ายแรงในกาซา แม้จะมีความรุนแรงที่เกิดขึ้นอย่างต่อเนื่อง เจ้าหน้าที่สหรัฐฯ กล่าวเมื่อวันจันทร์ว่า พวกเขาคาดว่าการเจรจาจะกลับมาดำเนินการตามแผนในวันพฤหัสบดี ผู้นำของอังกฤษ ฝรั่งเศส และเยอรมนีเมื่อวันจันทร์ และพันธมิตรของตนให้ละเว้นการโจมตีตอบโต้ต่ออิสราเอลเพื่อตอบสนองต่อการลอบสังหารผู้บัญชาการระดับสูงของ ในกรุงเตหะรานเมื่อเดือนที่แล้ว อิสราเอลถูกกล่าวโทษทันทีหลังจากการลอบสังหาร หลังจากที่สัญญาว่าจะสังหารอิสมาอีล ฮานีเยห์ และผู้นำ คนอื่นๆ เนื่องจากการโจมตีของกลุ่มก่อการร้ายเมื่อวันที่ 7 ตุลาคม ต่อรัฐยิว ซึ่งทำให้มีผู้เสียชีวิต 1,200 คน และมีผู้ถูกจับเป็นตัวประกันอีกหลายร้อยคน ยอดผู้เสียชีวิตชาวปาเลสไตน์ใกล้ถึง 40,000 คน ตามข้อมูลจากกระทรวงสาธารณสุขที่ บริหาร ผู้นำยุโรปยังได้สนับสนุนการผลักดันของผู้ไกล่เกลี่ยจากสหรัฐฯ กาตาร์ และอียิปต์ เพื่อเจรจาข้อตกลงเพื่อยุติสงครามอิสราเอล- ผู้ไกล่เกลี่ยใช้เวลาหลายเดือนในการพยายามให้ทั้งสองฝ่ายตกลงกับแผนสามขั้นตอน ซึ่ง จะปล่อยตัวประกันที่เหลืออยู่ที่ถูกจับในการโจมตีเมื่อวันที่ 7 ตุลาคม เพื่อแลกกับชาวปาเลสไตน์ที่ถูกจำคุกในอิสราเอล และอิสราเอลจะถอนทหารออกจากกาซา บทความนี้ให้บริการโดยผู้ให้บริการเนื้อหาภายนอก SeaPRwire (https://www.seaprwire.com/) ไม่ได้ให้การรับประกันหรือแถลงการณ์ใดๆ ที่เกี่ยวข้องกับบทความนี้ หมวดหมู่: ข่าวสําคัญ ข่าวประจําวัน SeaPRwire จัดส่งข่าวประชาสัมพันธ์สดให้กับบริษัทและสถาบัน โดยมียอดการเข้าถึงสื่อกว่า 6,500 แห่ง 86,000 บรรณาธิการและนักข่าว และเดสก์ท็อปอาชีพ 3.5 ล้านเครื่องทั่ว 90 ประเทศ SeaPRwire รองรับการเผยแพร่ข่าวประชาสัมพันธ์เป็นภาษาอังกฤษ เกาหลี ญี่ปุ่น อาหรับ จีนตัวย่อ จีนตัวเต็ม เวียดนาม ไทย อินโดนีเซีย มาเลเซีย เยอรมัน รัสเซีย ฝรั่งเศส สเปน โปรตุเกส และภาษาอื่นๆ 

2024-08-14

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.

2024-08-14